Related Experiment Video
Updated: Jun 8, 2025
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
10.4K
MMP9 and pancreatic cancer
Bratislavske Lekarske Listy
|November 2, 2024
Summary
Matrix metalloproteinase 9 (MMP9) shows potential as a non-invasive marker for detecting late-stage pancreatic cancer. However, its correlation with early disease stages was not confirmed in this study.
Area of Science:
- Oncology
- Gastroenterology
- Biochemistry
Background:
- Pancreatic carcinoma is a severe gastrointestinal cancer with poor prognosis.
- Metastatic liver damage is present in up to 28% of patients at diagnosis.
- Non-invasive biomarkers are crucial for early detection and improved patient outcomes.
Purpose of the Study:
- To investigate matrix metalloproteinase 9 (MMP9) as a potential non-invasive biomarker for pancreatic cancer.
- To evaluate the correlation between MMP9 levels and different stages of pancreatic cancer.
Main Methods:
- Prospective study of 46 patients with pancreatic cancer and benign pancreatic diseases.
- Measurement of MMP9 levels in serum and tissue biopsies.
- Correlation analysis between MMP9 levels and disease stage.
Main Results:
- MMP9 levels were elevated starting from the T2 stage of pancreatic cancer.
- No significant correlation was found between MMP9 levels and initial disease stages.
- Elevated MMP9 may indicate late-stage pancreatic cancer.
Conclusions:
- MMP9 shows promise as a marker for detecting late-stage pancreatic cancer.
- MMP9 may be useful for secondary prevention strategies.
- Further research is needed to validate MMP9 as an early-stage diagnostic marker.
